Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-06
2005-12-06
Campbell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S018700, C530S300000, C530S317000, C530S321000, C530S331000
Reexamination Certificate
active
06972281
ABSTRACT:
The invention relates to new basic amino acid derivatives of general formula I and the preparation and use thereof in treatment of pain. The compounds have histogranin-like antinociceptive, morphine potentiating and COX-2 induction modulating activities.wherein:A is -hydrogen, —(C1-C8)alkyl or —(C1-C8)alkyl substituted by hydroxy;B is —(C1-C6)alkylguanidino, —(C1-C6)alkyl(4-imidazo-lyl), —(C1-C6)alkylamino, p-aminophenylalkyl(C1-C6)—, p-guanidinophenylalkyl(C1-C6)— or 4-pyridinylalkyl(C1-C6)—;R1, R2and R3are, independent of one another, -hydrogen, -arylcarbonylamino, —(C1-C6)alkoylamino, —(C1-C6)alkylamino, —(C1-C6)alkyloxy, —(C1-C6)alkylaminocarbonyl, -carboxy, —OH, -benzoyl, -p-halogenobenzoyl, -methyl, —S-(2,4-dinitrophenyl), —S-(3-nitro-2-pyridinesulfenyl), -sulfonyl, -trifluoromethyl, —(C1-C6)alkylaminocarbonylamino, -halo or -amino;R4and R5are, independent of one another, -hydrogen, —(C1-C6)alkyl, -methyloxy, -nitro, -amino, -arylcarbonylamino, —(C1-C6)alkoylamino, —(C1-C6)alkylamino, -halo or —OH.
REFERENCES:
patent: 5169833 (1992-12-01), Hansen, Jr. et al.
patent: 6566327 (2003-05-01), Lemaire
patent: 2219437 (1999-04-01), None
patent: 0419210 (1991-03-01), None
Lemaire, et al. “Isolation and characterization of histogranin, a natural peptide with NMDA receptor antagonist activity.” Eur. J. Pharmacol.—Molec. Pharmacol. Sec. (1993) 245:247-256.
Boarder, et al. “Met-enkephalin [Arg6,Phe7] immunoreactivity in bovine caudate adrenal medulla.” J. Neurochem. (1982) 39(1):149-154.
Liston, et al. “Processing of proenkephalin is tissue-specific.” Science. (Aug. 17, 1984) 734-737.
Lemaire, et al. “Central and peripheral non-opioid analgesic activity of histogranin and related peptides.” Soc. Neurosci. (1997) 23:674, abstract no. 267.13.
Ruan, et al. “Non-opioid antinociceptive effects of supraspinal histogranin and related peptides: possible involvement of central dopamine D2receptor.” Pharmacol. Biochem Behav. (2000) 67:83-91.
Shukla, et al N-methyl-D-aspartate receptor antagonist activity and phencyclidine-like behavioral effects of the pentadecapeptide, [Serl]histogranin. Pharmacol. Biochem Behav. (1995) 50(1):49-54.
Siegan, et al. “A natural peptide with NMDA inhibitory activity reduces tonic pain in the formalin model.” NeuroReport. (1997) 8:1379-1381.
Siegan, et al. “Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity.” Brain Research. (1997) 755:331-334.
Hama, et al. “NMDA-induced spinal hypersensitivity is reduced by naturally derived peptidee analog [Serl]histogranin.” Pharmacol. Biochem. Behav. (1999) 62(1):67-74.
Rogers, et al. “Characterization of [125I][Serl]histograninh binding sites in rat brain.” J. Pharmacol. Exper. Ther. (1993) 267(1):350-356.
Lemaire, et al. “Characterization of histogranin receptors in human peripheral blood hymphocytes.” Biochem. Biophys. Res. Comm. (1993) 194(3):1323-1329.
Nishino, et al. “Cyclo(-arginyl-sarcosyl-aspartyl-phenylglycyl-)2. Simple synthesis of an RGD-related peptide with inhibitory activity for platelet aggregation.” J. Chem Soc., Perkin Trans. I. (1996) 939-946.
Osapay, et al. “Synthesis of tyrocidine A: Use of oxime resin for peptide chain assembly and cyclization.” Tetrahedron Letters. (1990) 31(43):6121-6124.
Kaiser, et al. “Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides.” Anal. Biochem. (1970) 34:595-598.
Matsueda, et al. “A p-methylbenzhydrylamine resin for improved solid-phase synthesis of peptide amines.” Peptides. (1981) 2:45-50.
Lee, et al. “Solid phase synthesis of 3,4-disubstituted-7-carbamoyl-1,2,3,4-tetrahydroquinoxalin-2-ones.” J. Org. Chem. (1997) 62:3874-3879.
Backes, et al. “Activation method to prepare a highly reactive acysulfonamide “safet-catch” linker for solid-phase synthesis.” J. Am. Chem. Soc. (1996) 118:3055-3056.
Lemaire. et al. “Synthesis and biological activity of dynorphin-(1-13) and analogs substituted in positions 8 and 10.” Int. J. Peptide Protein Res. (1986) 27:300-305.
Shukla, et al. “Selective involvement of kappa opioid and phencyclidie receptors in the analgesic motor effects of dynorphin-A-(1-13)-Tyr-Leu-Phe-Asn-Gly-Pro.” Brain Research. (1992) 591:176-180.
Hayashi, et al. “The type of analgesic-receptor interaction involved in certain analgesic assays.” Eur. J. Pharmacol. (1971) 16:63-66.
D'Amour, et al. “A method for determining loss of pain sensation.” J. Pharmacol. Exp. Ther. (1941) 72:74-79.
Verma, et al. “Role of D1/D2 dopmaine and N-methyl-D-aspartate (NMDA) receptors in morphine tolerance and dependence in mice.” Eur. Neuropsychopharmacol. (Jun., 1995) 5(2):81-87. Pub. Med. Abstract PMID 7549459.
Sufka, et al. “Stimulus properties and antinociceptive effects of selective bradykinin B1and B2receptor antagonists in rats.” Pain. (1996) 66:99-103.
Lemaire, Irma “Characterization of the bronchoalveolar cellular response in experimental asbestosis.” Am. Rev. Respir. Dis. (1985) 131:144-149.
Bernatchez-Lemaire Irma
Le Hoang-Thanh
Lemaire Simon
Campbell Bruce R.
Kosar Andrew D.
University of Ottawa
Welsh & Katz Ltd.
LandOfFree
Histogranin-like peptides and non-peptides, processes for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histogranin-like peptides and non-peptides, processes for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histogranin-like peptides and non-peptides, processes for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3485653